Fate Therapeutics INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Fate Therapeutics, a clinical-stage biopharmaceutical company, reported reduced net losses in 2025 while advancing its iPSC-derived cellular immunotherapy pipeline for autoimmune diseases and cancer.
NASDAQ
Fate Therapeutics' 10-K filing highlights advancements in its iPSC-derived cell therapy pipeline, particularly in autoimmune diseases and solid tumors, with ongoing clinical trials and strategic partnerships.
NASDAQ
Fate Therapeutics and Ono Pharmaceutical Co., Ltd. have amended their collaboration agreement, increasing the estimated annual collaboration budget for research and development.